Researchers from Germany have evaluated the eactogenicity profile of heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination among healthcare workers. The findings reveal that a 12-week interval regimen of heterologous vaccination is well-tolerated among participants. The study is currently published on a preprint server. In the entire study cohort, the reactogenicity data after the first vaccination with BNT162b2 or ChAdOx1 nCoV-19 were available for 178 and 148 participants, respectively.
Similarly, the reactogenicity data after homologous BNT162b2/BNT162b2 and heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccinations were available for 159 and 71 participants, respectively. In the heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination group, two doses of respective vaccines were administered at an interval of 12 weeks. Compared to heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination, ChAdOx1 nCoV-19 prime vaccination was associated with more frequent severe systemic reactions including fatigue, myalgia, headache, chills, and high fever.
The study findings reveal comparable reactogenicity for homologous BNT162b2/BNT162b2 and heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccinations. Among study participants, heterologous prime-boost vaccination exhibits a well-tolerated profile. Based on the study findings, the scientists recommend that immunizing people with the 1st dose of ChAdOx1 nCoV-19 vaccine and 2nd dose of BNT162b2 vaccine at an interval of 12 weeks can significantly reduce vaccine-associated reactogenicity.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here